1. Home
  2. Live Updates
  3. American society of nephrology kidney week

Live Breaking News & Updates on American society of nephrology kidney week

Stay informed with the latest breaking news from American society of nephrology kidney week on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in American society of nephrology kidney week and stay connected to the pulse of your community

How Vertex became the VIP of Alpine's exclusive data room

How Vertex became the VIP of Alpine's exclusive data room
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United-states , American , American-society-of-nephrology-kidney-week , Vertex-pharmaceuticals , World-congress , Alpine-immune-sciences , After-alpine-immune-sciences , American-society , Nephrology-kidney-week , San-francisco , Vertex-executive-chairman-jeffrey-leiden

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection

Chicago , Illinois , United-states , Philadelphia , Pennsylvania , Irvine , California , Massachusetts , American , Stephen-jasper , Eliezer-katz , David-alexandrec-gros

FDA Grants Orphan Drug Designation to Felzartamab for Kidney Transplant Recipients

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

United-states , American , Uptal-patel , Drug-administration-for-primary-membranous-nephropathy , American-society-of-nephrology-kidney-week , Orphan-drug-designation , Human-immunology-biosciences , American-society , Nephrology-kidney-week , Breakthrough-therapy-designation , Bio-receives , Drug-designation

Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

22.02.2024 - Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch off to a strong start, ...

United-states , Japan , Philadelphia , Pennsylvania , Canada , China , Japanese , American , Fosun-pharma , Arnold-silva , Mike-raab , Caitlin-lowie

Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0

United-states , Canada , Philadelphia , Pennsylvania , Japan , China , American , Japanese , Caitlin-lowie , Arnold-silva , Mike-raab , Philip-schoenfeld

Glycated Albumin Improves Prediction of Adverse CKD Outcomes

HbA1c is less reliable in patients with CKD. A study found that glycated albumin associates with important long-term clinical outcomes in a non-dialysis CKD population.

United-states , Massachusetts , Boston , China , Nanchang , Jiangxi , American , Gaosi-xu , Mengyao-tang , Second-affiliated-hospital-of-nanchang-university , American-society-of-nephrology-kidney-week , American-society

Glycated Albumin Improves Prediction of Adverse CKD Outcomes

HbA1c is less reliable in patients with CKD. A study found that glycated albumin associates with important long-term clinical outcomes in a non-dialysis CKD population.

Nanchang , Jiangxi , China , Massachusetts , United-states , Boston , American , Gaosi-xu , Mengyao-tang , Second-affiliated-hospital-of-nanchang-university , American-society-of-nephrology-kidney-week , American-society

72-Week Phase 2B ORIGIN Data Highlight Potential Benefit of Atacicept in IgA Nephropathy

The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators

United-states , American , Marshall-fordyce , Budesonide-tarpeyo , Richard-lafayette , American-society-of-nephrology , Stanford-health-care-richard-lafayette , American-society-of-nephrology-kidney-week , Stanford-health-care , Vera-therapeutic , Stanford-glomerular-disease-center , Stanford-university-medical

Elevated urinary albumin tied to sub-clinical cardiovascular disease in diabetes patients

Denmark: A recent study revealed that elevated albumin in the urine may be linked with sub-clinical coronary artery pathology, including coronary artery microcalcifications in individuals with type 2...

Copenhagen , Køavn- , Denmark , United-states , American , Steno-diabetes-center-copenhagen , American-society-of-nephrology-kidney-week , American-society , Kidney-week , Tine-hansen , Coronary-artery-pathology

Condition State Management: Diabetes

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.

Pennsylvania , United-states , Vienna , Wien , Austria , Philadelphia , American , Eli-lilly , Aislinn-antrim , Ashley-gallagher , Erin-hunter , Johannes-kovarik